WETTABLE POWDER COMPOSITIONS OF IONOPHORE ANTIBIOTICS

Abstract: A dry composition of an ionophore antibiotic such as monensin comprising from 10 to 95 % (when expressed as the sodium salt) of at least one crystalline ionophore antibiotic, from 0 to 10 % antifoam agent(s), from 0.1 to 20 % wetting and/or surfactant agent(s), from 0.1 to 10 % dispersal agent(s), and from 0.1 to 20 % suspension agent(s). The use of the composition is as a suspension in water alone or in conjunction with a milk replacer composition and/or a milk extender composition in water as a calf feed composition.

Description: WETTABLE POWDER COMPOSITIONS OF IONOPHORE ANTIBIOTICS TECHNICAL FIELD The present invention relates to wettable powder compositions of an ionophore antibiotic useful as a feed supplement to a ruminant animal (including a suckling ruminant juvenile animal), methods of using such a composition in conjunction with milk and/or milk replacement powders and as a milk replacer for such ruminant animals and related means and methods. BACKGROUND ART In US Patent 3839557 of Eli Lilly and Company (the full content of which is hereby here incoφorated by reference) there is disclosure of a method of increasing the efficiency of feed utilisation by ruminant animals having a developed rumen function where an antibiotic chosen from the group A204 (US Patent 3705238) dianemycin (fermentation product of Streptomyces Hygroscopicus NRRL 3444) monensin (US Patent 501358), X537A (Netherlands patent 70.12,108) nigericin (US Patent 3555150) and X206 (1951, Berger et al, J. Am Chem. Soc. 73, 5295-98 (1951)), and certain derivatives thereof, are orally administered to the ruminant animals whose feed efficiency is to be increased. Examples of appropriate ruminant animals given are cattle, sheep and goats. The invention of US Patent 3839557 is indicated as being useful to ruminants which have a developed rumen function. Young ruminants (basically those still unweaned) are stated as functioning as monogastric animals and that it is not until such young ruminant eat solid feed containing cellulose, starch and other carbohydrates that the function ofthe rumen begins to develop and the microbiological population ofthe rumen increases. Dosages given in US Patent 3839557 (in general propionate-increasing amounts) are in the range of from about 0.05mg of antibiotic per kg of body weight per day to about 2.5mg/kg/day. Administration methods given in US Patent 3839557 suggest incorporation ofthe antibiotic compound or compounds into tablets, drenches, boluses or capsules. There is disclosure that drenches of such antibiotics can be prepared most easily by choosing a water soluble form ofthe antibiotic but that if an insoluble form is desired for some reason a suspension can be made. There is an mdication that suspensions of insoluble forms of the antibiotics can be prepared in non solvents such as water but that suitable physiologically-acceptable adjuvants are necessary in order to keep the antibiotics suspended. The adjuvants can be chosen from amongst thickeners, surfactants, hydrophilicity agents, density affecting agents and surface tension affecting agents. US Patent 3839557 suggests that a suspendible antibiotic may be offered as a dry mixture ofthe antibiotic in adjuvants to be diluted before use. A suggestion is made that such antibiotic can be incorporated into drinking water by adding a water soluble or water suspendible form ofthe desired antibiotic to the water in a proper amount. There is also disclosure that the method of administration of the antibiotic can be practised in combination with other treatments, ie. with other drugs used in combination. European Patent Application 0139595 of Koffolk (1943) Limited relates to liquid feeds and milk replacers for ruminants and particularly for suckling ruminants. Such compositions that are disclosed contain ionophore antibiotics such as monensin, narasin, lasalocid (US Patent 3715372) and solinomycin. In one form ofthe invention of EP 0139595 there is disclosed a liquid ionophore antibiotic composition for ruminants comprising an ionophore antibiotic and at least one non toxic water miscible organic solvent. The invention is also stated as providing a dry water soluble ionophore antibiotic composition suitable for combination with an aqueous medium to form a liquid composition for ruminants, the composition comprising an ionophore antibiotic, a non toxic water miscible organic solvent and a dry water soluble carrier therefor. The invention relates also to process for preparing liquid feeds which involves dissolving such an ionophore antibiotic in a non toxic water soluble organic solvent and admixing the resulting solution with a liquid feed, a water soluble vitamin concentrate or with drinking water. The preferred ionophore antibiotics are those that have been subjected to an extraction process whereby the antibiotic is no longer in the mycelial form, ie. is in a crystallisable form or a crystalline form. Such compositions of EP 0139595 are stated as being liquid milk replacers, or at least being capable of being incoφorated in liquid feeds or drinking water for administration to a suckling ruminant. Example 13 of EP 0139595 refers to spraying in a horizontal mixer ofa monensin solution (ofthe invention of EP 0139595 as defined) on a dry milk replacer and then the subsequent "dissolving" thereof with water. DISCLOSURE OF INVENTION The present invention relates to an alternative milk replacer or milk extender composition to any of those disclosed and to related methods. In a first aspect the present invention consists in a dry composition of an ionophore antibiotic capable of being suspended in water directly to form a suspension (with or without any other addition(s)) deliverable into a ruminant (particularly a suckling ruminant) or, capable upon admixture with a dry milk powder and/or milk substitute powder, of in turn then being mixed with water to form (with or without any other addition(s)) a suspension deliverable into a ruminant (particularly a suckling ruminant) as a milk replacement or extender, said composition comprising, when expressed weight for weight with respect to the overall dry composition, from 10 to 95% (when expressed as the sodium salt) of at least one crystalline ionophore antibiotic, from 0 to 10% antifoam agent(s), from 0.1 to 20% wetting and/or surfactant agent(s), from 0.1 to 10% dispersal agent(s), and from 0.1 to 20% suspension agent(s). As used herein percentages of ionophore antibiotic refer to the antibiotic in any suitable form (eg. acid or salt) but expressed for the puφose ofthe ranges by reference to its weight as the sodium salt as against the overall weight to the dry composition (where for the puφose ofthe overall weight the antibiotic is also accounted for by reference to its weight as the sodium salt). Preferably said antibiotic is from 90 to 95% w/w Preferably said antifoam agents is from 0 to 2% w/w Preferably said wetting/surfactant agents is from 0.1 to 5% w/w. Preferably said dispersal agent is from 0.1 to 5% w/w Preferably said suspension agent is from 0.1 to 5% w/w. A preferred composition has from 10 to 95% (eg. 10 to 80%) of at least one crystalline ionophore antibiotic, from 0.1 to 0.5% antifoam agent(s), from 0.1 to 0.5% wetting and or surfactant agent(s), from 0.1 to 0.5% dispersal agent(s), and from 0.1 to 0.5% suspension agent. Preferably said ionophore antibiotic is selected from group consisting of Monensin, Lonomycin, Ionomycin, Laidlomycin, Nigericin, Grisorixin, Dianemycin, Lenoremycin, Salinomycin, Narasin, Antibiotic X206, Alborixin, Septamycin, Antibiotic A204, Maduramicin and Semduramicin, Compound 47224, Lasalocid (also including factors A, B, C, D and E), Mutalomycin, Isolasalocid A, Lysocellin, Tetronasin, Echeromycin, Antibiotic X- 14766A, Antibiotic A23187, Antibiotic A32887, Compound 51532 and K41. Preferably said ionophore antibiotic is Monensin. Preferably said Monensin is Sodium Monensin. Preferably said antifoaming agent is selected from the group consisting of Silicone antifoam powder such as Wacker ASP 3 hereinafter referred to. Preferably said wetting agent is selected from the group consisting of Sodium lauryl sulfate (anionic sulfates) such as CARSONOL™ SLS-R (LONZA) or EMAL™ (POLEKAO). Preferably said dispersal agent is selected from the group consisting of colloidal anhydrous silica such as Aerosil 200 Chemische Fabrik Kirsh Gmbtt. Preferably said suspension agent(s) is or are selected from the group consisting of refined food grade galactomannan such as guar gum. In a further aspect the present invention consists in the use of a dry composition in accordance with the present invention after admixture with water to form a suspension as a feed supplement ofa suckling or other ruminant. Preferably said use involves milk powder or a milk substitute which is mixed into water either subsequently to, simultaneously with or prior to the suspension of the composition ofthe present invention in such water. The present invention also consists in, as a dry composition, a dry composition in accordance with the present invention and a milk powder and/or milk replacement powder. In yet a further aspect the invention consists in a calf feed composition comprising a substantially homogeneous aqueous suspension of, with respect to the composition volume, (i) from 2 to 16 mg/L of a dry composition in accordance with the present invention, (ii) optionally, a milk replacer composition, and (iii) optionally, a milk extender composition. Preferably from 5 to 30 g/L ofa dry milk replacer composition has been included. Preferably 10 to 25 g/L, eg. 15, or 20 g/L. Preferably from 1 to 3 g/L milk extender (preferably about 2 g/L) is present or, preferably, is present in addition to a or the dry milk replacer composition. In yet a further aspect the invention consists in a dry composition of monensin capable of being suspended in water directly to form a suspension (with or without any other addition(s)) deliverable into a ruminant or, capable upon admixture with a dry milk powder and/or milk substitute powder, of in turn then being mixed with water to form (with or without any other addition(s)) a suspension deliverable into a ruminant as a milk replacement or extender, said composition comprising, when expressed weight for weight with respect to the overall dry composition, 95% (when expressed as the sodium salt), of crystalline sodium monensin, 19% silicone antifoam powder, 3.5% sodium lauryl sulfate, 2.5% colloidal anhydrous silica, and 1.5% Guar gum. In a still further aspect the invention consists in a calf feed composition comprising a substantially homogeneous aqueous suspension of, with respect to the composition volume, (I) from 2 to 16 mg/L ofa composition comprising 95% (when expressed as the sodium salt) of crystalline sodium monensin, 19% silicone antifoam powder, 3.5% sodium lauryl sulfate, 2.5% colloidal anhydrous silica, and 1.5% Guar gum, AND (II) 15 to 20 g/L of a milk replacer composition, and/or 1 to 3 g/L of a milk extender composition. In still a further aspect the invention consists in, as a premix. The components (i) and (ii), (i) and (iii) or (i), (ii) and (iii) for a calf feed composition as defined hereinbefore. In still a further aspect the present invention consists in a method of increasing feed conversion and growth rate of suckling ruminants which involves the administration orally or self administration orally of a composition of the present invention in conjunction with at least water into such ruminants. Coccidiosis is a serious and common disease of dairy calves. During much ofthe time that dairy calves are at risk of coccidiosis, some or all or their diet comprises milk, milk replacers or milk extenders. The intake of these milk components is more consistent and controllable than other components of the diet. For this reason it is desirable to be able to administer anti-coccidial agents to these animals in the milk portion of their diet. Monensin sodium in prior art formulations does not remain evenly distributed in milk, milk replacers or milk extenders for a sufficient period time to make it practical or safe for use in this manner. A "milk extender" contains vitamins and minerals but in itself is not a "milk replacer". Milk replacers are, as the name suggests, compositions capable of replacing the natural milk of the species. Typically a milk replacer is made up from a skim milk powder (usually ofthe same species of mammal) plus a source of fat which can either be of animal or plant origin. In the case of cattle this fat replaces the normal cream in whole cows milk. The present invention therefore envisages a calf feed to supplement or replace the natural milk feed of an animal. The calf feed may comprise i) a milk replacer having an anti coccidial agent provided in accordance with the present invention, substantially evenly distributed there throughout ii) a milk replacer and milk extender mixed/blended composition itself including an anti coccidial agent (whether blended with the milk replacer, the milk extender or both simultaneously). Calves receive and ingest milk replacers and extenders within 24 hours of preparation. Monensin was selected as the ionophore antibiotic tor detailed trialing. To ensure the safety of monensin wettable powder as a delivery vector for ingestion as a liquid it was considered necessary that monensin, delivered as part ofa calf feed eg. An aqueous composite as a milk replacer and/or milk extender, should remain evenly distributed for 24 hours after homogeneous mixing with water. The puφose of these trials was to determine the distribution characteristics of monensin wettable powder in aqueous preparations of milk replacers and milk extenders. A preferred form of monensin wettable powder ofthe present invention having the formula as follows was used in the following trials and assays. MONENSIN (Sodium) WETTABLE POWDER A preferred dry composition of an ionophore antibiotic (this includes a mixture of different types) comprises 10 to 95% of at least one crystalline ionophore antibiotic (the percentage being when the antibiotic is expressed as its sodium salt (eg. Monensin sodium whether or not it is in fact a monensin salt or indeed a sodium salt), 0 to 2% antifoam agent(s), 0.1 to 5% wetting and/or surfactant agent(s), 0.1 to 5% dispersal agent(s), and 0.1 to 5% suspension agent. BRIEF DESCRIPTION OF DRAWINGS A most preferred formulation and that trialed as described hereinafter by reference to Figures 1 to 11 was prepared as now follows: Blended in cube blender for 10 minutes, low speed: RUMENSIN™ Technical Elanco Animal Health (Monensin sodium) division of Eli Lilly Australia Pty Ltd, 112 Wharf Road, NSW 2114, Australia EL5167 915g (929 gai/Kg) Silicone Antifoam Powder Wacker Silicone 10g ASP3 available from Arncor Trading, PO Box 33 Drumoyne NSW 2047 Australia EMAL™ 10 NEEDLE 35g sodium lauryl sulfate PT Polekao Indonesia Chemicals available in Australia from P & M O'Brien Trading Pty Ltd, ACN 054787161 (Lot No.1410) AEROSIL 200™ Chemische Fabrik Kirsh 25g (colloidal anhydrous silica) GmbH Product Code HH01 available in Australia from Chemical Distributors Fax 61 2 9385867 Guar gum Woods or Woods Pty Ltd WW 250 F ACN 001 092 066 15 (galactomannan E412) Australia lOOOg Monensin sodium wettable powder was formulated this to enable monensin to remain evenly distributed in aqueous calf feed compositions for a period of 24 hours. Calf Feed Components of Trials: Milk Replacer VEANAVITE™ Instant Calf Milk replacer 13426 - available from Philip Grant, PO Box 160, Cowra, NSW 2794, Australia. Milk Extenders PREMAX™ Calf Booster [available from Ridley Agriproucts Pty Ltd 39 Oxford Street, Epping, NSW 2121, Australia.] CALFGO™ (Rhone Poulenc) B/N 55654 [available from Rhone Poulenc Animal Nutrition 19-25 Paramount Road, West Footscray, Victoria 3012, Australia.] Monensin (sodium) MONENSIN (sodium) (RUMENSIN™) WETTABLE POWDER (B/N 470 Assay No. 950103 (86.7%)) ofthe present invention ie. The blend resulting from the immediately preceding formulation. Water COW'S MILK STANDARD The wettable powder of the present invention was developed for use in milk replacers which may additionally include milk extenders. It is the suspendability ofthe wettable powder in such aqueous compositions of milk replacers additionally enhanced where desired by milk extenders, that is of importance. For this reason therefore the suspendability of monensin wettable powder in water was not considered a useful standard as both milk and milk replacer based aqueous compositions are much more complex liquids than mere water particularly in regard to the fat, sugar, and protein present. It was therefore considered that for the p pose of assaying for the strengths of monensin during the trials an appropriate standard for comparative puφoses (the assay for monensin) was a known strength composition of monensin sodium in whole cows milk. First a known strength (8000 mg/L) crystalline monensin sodium solution in methanol was prepared. This was then used to formulate the assay standard formulations (the methanol having been evaporated by a stream of nitrogen) after pipetting of amounts ofthe monensin/methanol into 2 litre volumetric flasks as follows: Monensin concentration in (mL) ofthe Whole Cows milk(mg L)(as expressed as monensin/methanol solution Milk (L) Monensin and not the salt) 2 0.5 2 6 1.5 2 8 2.0 2 12 3.0 2 16 4.0 2 The monensin in milk concentrations were achieved by the addition of cow's milk into the volumetric flask. INMILKREPLACERSWITHMILKEXTENDERS It is anticipated that for commercial use monensin wettable powder will be added to aqueous calf feed compositions (milk replacers optionally with milk extenders) at a rate of 6 mg/L monensin. The addition rates of monensin used in this trial were chosen to represent a range around this anticipated use rate (ie. 2, 6, 8, 12, 16 mg/L). For the puφose ofthe trials the milk replacer used was VEANAVITE™ instant calf milk replacer identified above. Two formulations of milk extender (formulations 1 and 11) were examined in this trial. Both formulations are of commercial milk extenders currently used in the Australian market. [PREMAX™ Calf Booster] Milk Extender Formulation I Per kg Retinyl acetate (vitamin A) 186,000IU Cholecalciferon (vitamin D 3 ) 18,000IU di-alpha-tocopheryl acetate (vitamin E) 1.86 g Thiamine hydrochloride 400 mg Pyridoxine hydrochloride 150 mg Cyanocobalamin 20 mg Biotin 3.0 mg Folic acid 8.0 mg Menadione 65.0 mg Nicotinic acid 696.0 mg D-calcium pantothenate 262.0 mg Choline 67.86 mg Selenium (Se) 1.0 mg Cobalt (Co) 3.0 mg Iodine (I) 15.0 mg Copper (Cu) 292.0 mg Manganese (Mn) 749.0 mg Zinc (Zn) 900.0 mg Ferrous iron (Fe++) 1.13 g Lysine 2.00 g di-Methlonine 2.00 g Magnesium (Mg) 469.97 g Maximum fluorine (F) Nil Carrier Prebase™ ? [CALGRO™] Milk Extender Formulation II Per kg Vitamin A 40,000 IU Vitamin D 6,000 Vitamin E 80 mg Vitamin K 2 mg Thiamine (Bl) 6 mg Riboflavin (B2) 7 mg Pyridoine (B6) 4 mg Niacin 20 mg B12 0.05 mg Biotin 1 mg Vitamin C 100 mg Pantothenic acid 13 mg Folic acid 0.006 mg Choline Chloride 200 mg Magnesium 300 mg Copper 10 mg Cobalt 0.8 mg Zinc 70 mg Iron 150 mg Iodine 0.8 mg Selenium 0.2 mg Manganese 50 mg Molybdenum 4 mg Avoparcin 40 mg Calf feed formulations trialled were prepared with water with 15g/L and 20g/L VEANAVITE™ Instant Milk replacer and either 2 g/L Premax Calf Booster or 2g/L Calfgro. 15g/L milk replacer / 2g L extender formulations were studied at Monensin sodium concentrations of 2 mg/L, 6 mg/L, 8 mg/L, 12 mg/L and 16 mg/L. 20g/L milk replacers /2g/L extender formulations were studied at a Monensin sodium concentration of 6 mg/L. Each monensin wettable powder spiked formulation was sampled at the top and bottom of the prepared volume at 0, 1, 3, 5 and 24 hours. Sample extraction was performed immediately and extracts analysed the same day. ANALYSES (i). Pipette two 40 mL portions for zero time analysis. (ii). At subsequent time points pipette a 40 mL portion from 2.5 cm under the surface (top sample) and 1.5 cm above the container bottom (bottom sample). (iii). Prepare extracts for HPLC analysis on each 40 mL portion as they are sampled. (iv). Analysis by HPLC. Monensin is extracted from various milk formulations with dichloromethane and is quantified using a high performance liquid chromatograph (LC) equipped with a post column reactor. Monensin is acid - reacted with vanillin, and the resulting products are measured by a variable wavelength visible detector operating at 520nm. The method is based on the Lilly Research Laboratories method AM-AA-CR- R150-AB-791. Milk replacer was prepared at 15 and 20g/L concentrations since the concentration of milk replacer received by calves is usually varied with the age ofthe calf. RESULTS Table 1: Suspension in water of monensin wettable powder with 15g/L milk replacer and 2g/L milk extender samples mg monensin Theoretical Position O Hr l Hr 3 Hr 5 Hr 24Hr mg monensin 2 mg/L Extender 1 Top 1.9 1.9 1.8 1.9 2.0 Bottom - 1.9 1.8 1.8 2.1 Extender 2 Top 1.9 1.8 1.8 1.8 2.0 Bottom - 1.8 1.9 1.8 2.0 6 mg/L Extender 1 Top 6.0 5.9 6.0 5.2 5.7 Bottom - 6.0 5.7 5.8 5.8 Extender 2 Top 6.3 6.2 6.1 6.1 6.1 Bottom - 5.8 5.7 5.7 6.1 8 mg/L Extender 1 Top 8.0 7.4 6.9 7.2 7.4 Bottom - 7.3 7.0 7.0 7.2 Extender 2 Top 8.0 8.1 8.4 8.0 7.6 Bottom - 7.7 7.7 7.6 7.9 12 mg/L Extender 1 Top 12.5 12.2 12.3 12.5 11.9 Bottom - 12.0 12.1 12.0 13.0 Extender 2 Top 12.4 11.9 11.3 11.7 11.3 Bottom - 12.0 11.6 11.5 11.8 16 mg/L Extender 1 Top 16.6 16.7 16.4 16.0 17.1 Bottom - 16.3 16.5 16.0 16.2 Extender 2 Top 16.7 16.2 16.1 16.0 15.6 Bottom - 16.2 16.1 15.6 15.8 Table 2: Suspension in water of Monensin wettable powder with 20g/L milk replacer and 2g L milk extender Spike Position O Hr 1 Hr 3 Hr 5 Hr 24 Hr 6 mg/L Extender 1 Top 6.0 5.9 5.8 5.7 5.9 Bottom 5.6 5.6 5.5 5.5 Extender 2 Top 6.0 5.6 5.6 5.7 5.6 Bottom 5.7 5.6 5.5 5.4 Monensin wettable powder remained evenly distributed in the 15g/L milk replacer solution at all concentrations of monensin for 24 hours after preparation. Please see Figures 1 to 10. Monensin wettable powder remained evenly distributed in the 20g/L milk replacer at 6 mg/L for 24 hours after preparation. Please see Figures 10, IIA and 1 IB- MIXING and APPLICATION A quantity of dry components whether mixed in together simultaneously or in any sequence is capable of easy blending in a cube blender requiring only about 10 minutes low speed blending. Mixture is then passed through a hammer mill to form a powder. Such a powder can then be blended with a dry milk powder or milk replacement powder and subsequently as required then be suspended along with the milk powder or milk replacement powder in water for delivery into the animal. Alternatively the composition can be directly suspended into water and if desired sprayed onto milk powder and then either immediately or subsequently that milk powder (or milk replacement powder or a mixture of both) can as required then be made up with additional water to provide the feed supplement for the animal including the ionophore antibiotic delivered by a composition ofthe present invention. Other methods of administration include separate suspension ofthe composition of the present invention in water and the suspension of milk powder or a milk powder substitute in water and then the bringing ofthe two suspensions together prior to delivery into the animal. They can if desired be serially administered to the animal. COMMENT A composition in accordance with the present invention has advantages over any foreshadowed in the aforementioned US Patent Specification 3839557 in that it allows delivery of the antibiotic to young suckling ruminants as part of their milk diet by incoφoration in the milk replacer powder during manufacture or at mixing of the milk replacer with water. This is more practical than dosing with a tablet, drenching or adding to water and over any disclosed in EP 0139595 in that no organic solvent for the ionophore antibiotic is a prerequisite. EP 0139595 discloses no example ofa composition not requiring an organic solvent. An omission of an organic solvent as a precursor to suspension in water of the antibiotic has several advantages • Monensin has poor solubility in all organic solvents except methyl alcohol (a poison to mammals) and n-propyl alcohol - when these solutions are added to water monensin crystallises out of solution • other features - non flammable - no odour - no separation problems (as above) - cost effective - simple manufacturing process - high concentration of active monensin - easily mixed with powders, water and can be sprayed - better stability in a powder form.

Claims: CLAIMS: 1. A dry composition of an ionophore antibiotic capable of being suspended in water directly to form a suspension (with or without any other addition(s)) deliverable into a ruminant or, capable upon admixture with a dry milk powder and/or milk substitute powder, of in turn then being mixed with water to form (with or without any other addition(s)) a suspension deliverable into a ruminant as a milk replacement or extender, said composition comprising, when expressed weight for weight with respect to the overall dry composition, from 10 to 95% (when expressed as the sodium salt) of at least one crystalline ionophore antibiotic, from 0 to 10% antifoam agent(s), from 0.1 to 20% wetting and/or surfactant agent(s), from 0.1 to 10% dispersal agent(s), and from 0.1 to 20% suspension agent(s). 2. A composition of claim 1 wherein said antibiotic (when expressed as the sodium salt) is from 90 to 95% w/w. 3. A composition of claim 1 wherein said antifoam agent(s) is from 0 to 2% w/w. 4. A composition of claim 1 wherein said wetting/surfactant agents is from 0 to 5% w/w. 5. A composition of claim 1 wherein said dispersal agent is from 0.1 to 5% w/w. 6. A composition of claim 1 wherein said suspension agent is from 0.1 to 5% w/w. 7. A composition of claim 1 comprising from 10 to 95% (when expressed as the sodium salt) of at least one crystalline ionophore antibiotic, from 0.1 to 0.5% antifoam agent(s), from 0.1 to 0.5% wetting and/or surfactant agent(s), from 0.1 to 0.5% dispersal agent(s), and from 0.1 to 0.5% suspension agent. 8. A composition of any one ofthe preceding claims wherein said ionophore antibiotic is selected from group consisting of Monensin, Lonomycin, Ionomycin, Laidlomycin, Nigericin, Grisorixin, Dianemycin, Lenoremycin, Salinomycin, Narasin, Antibiotic X206, Alborixin, Septamycin, Antibiotic A204, Maduramicin and Semduramicin, Compound 47224, Lasalocid (also including factors A, B, C, D and E), Mutalomycin, Isolasalocid A, Lysocellin, Tetronasin, Echeromycin, Antibiotic X-14766A, Antibiotic A23187, Antibiotic A32887, Compound 51532 and K41. 9. A composition of claim 8 wherein said ionophore antibiotic is monensin in the acid or a salt form. 10. A composition of claim 9 wherein said monensin is included in the form of sodium monensin. 11. A composition of claim 1 or 3 wherein said antifoaming agent(s) is or includes silicone antifoam powder. 12. A composition of claim 1 wherein said wetting agent(s) is or includes an anionoic sulfate. 13. A composition of claim 12 wherein said anionic sulfate is sodium lauryl sulfate. 14. A composition of claim 1 or 5 wherein said dispersal agent(s) is or includes a colloidal anhydrous silica. 15. A composition of claim 1 or 6 wherein said suspension agent(s) is or includes a galactomannan. 16. A composition of claim 15 wherein said suspension agent(s) is guar gum. 17. The use ofa dry composition in accordance with any one ofthe preceding claims after admixture with (at least) water to form a suspension as a feed supplement of a suckling or other ruminant. 18. The use of claim 17 further involving milk powder or a milk substitute which is mixed into water either subsequently to, simultaneously with or prior to the suspension ofthe composition ofthe present invention in such water. 19. As a dry composition, a dry composition in accordance with any one of claims 1 to 16 and a milk powder and/or milk replacement powder. 20. A calf feed composition comprising a substantially homogeneous aqueous suspension of, with respect to the composition volume, (i) from 2 to 16 mg/L of a dry composition as claimed in any one of claims 1 to 16, (ii) optionally, a milk replacer composition, and (iii) optionally, a milk extender composition. 21. A composition of claim 20 wherein from 5 to 30 g/L of a dry milk replacer composition has been included. 22. A composition of claim 20 wherein from 15 to 20 g/L of dry milk replacer composition has been included. 23. A composition of any one of claims 20 to 22 wherein from 1 to 3 g/L of dry milk extender has been included. 24. A composition of claim 23 wherein about 2g/L of milk extender has been included. 25. As a premix, the dry components of (i) and (ii), (i) and (iii) or (i), (ii) and (iii) of and suitable for a calf feed composition as defined in any one of claims 20 to 24. 26. A method of increasing feed conversion and growth rate of suckling ruminants which involves the administration orally or self administration orally ofa composition of any one of claims 1 to 16 in conjunction with at least water into such ruminants or a composition of any one of claims 20 to 24 into such ruminants. 27. A dry composition of monensin capable of being suspended in water directly to form a suspension (with or without any other addition(s)) deliverable into a ruminant or, capable upon admixture with a dry milk powder and/or milk substitute powder, of in turn then being mixed with water to form (with or without any other addition(s)) a suspension deliverable into a ruminant as a milk replacement or extender, said composition comprising, when expressed weight for weight with respect to the overall dry composition, 95% (when expressed as the sodium salt), of crystalline sodium monensin, 19% silicone antifoam powder, 3.5% sodium lauryl sulfate, 2.5% colloidal anhydrous silica, and 1.5% Guar gum. 28. A calf feed composition comprising a substantially homogeneous aqueous suspension of, with respect to the composition volume, (I) from 2 to 16 mg/L ofa composition comprising 95% (when expressed as the sodium salt) of crystalline sodium monensin, 19% silicone antifoam powder, 3.5% sodium lauryl sulfate, 2.5% colloidal anhydrous silica, and 1.5% Guar gum, AND (II) 15 to 20 g/L of a milk replacer composition, and or 1 to 3 g L of a milk extender composition.

Inventors: LOWE LIONEL BARRY, MOORE DEREK GEORGE, LOWE, LIONEL, BARRY, MOORE, DEREK, GEORGE
Applicants: ELI LILLY & COMPANY NZ LIMITED, LOWE LIONEL BARRY, MOORE DEREK GEORGE, ELI LILLY & COMPANY (NZ) LIMITED, LOWE, LIONEL, BARRY, MOORE, DEREK, GEORGE
Application year: 1996
Main classification: A61K31
IPC codes: A23K1, A61K9